PROPHASE LABS INC by ProPhase Labs, Inc. Analyst Price Targets - Benzinga

PROPHASE LABS INC by ProPhase Labs, Inc.

PRPHOTCID

Trade with Public

Trade with Public

$0.3626

At close: Jan 16, 4:00 PM EST

$0.0270

-0.34-92.55%

After Hours: Aug 24, 4:02 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare

PROPHASE LABS INC by ProPhase Labs, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for PROPHASE LABS INC by ProPhase Labs, Inc. (PRPH).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$11Upside to Avg. PT+40640.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Feb 21, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$11
Nov 10, 2023	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$14→$11

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $11 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $11 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on ProPhase Labs, Lowers Price Target to $11

HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and lowers the price target from $14 to $11.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $14 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $14 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $14 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $14 price target.

Benzinga Newsdesk

Analyst Expectations for ProPhase Labs's Future

Benzinga Insights

PRO
HC Wainwright & Co. Maintains Buy on ProPhase Labs, Lowers Price Target to $14

HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and lowers the price target from $15 to $14.

Benzinga Newsdesk